图片来自:医药魔方TrialCube数据库 打开网易新闻 查看精彩图片 此次公布的初步结果仅限于队列1和队列2。企业提供的22名患者数据显示,19名患者存在PACC-NCM或C797S突变,3名患者存在其他NCM突变。 打开网易新闻 查看精彩图片 安全性数据方面,截止2024年6月15日,共有40名患者随机分配到100 mg(n=20)或200 mg组(n=2...
MATERIALS/METHODS Recurrent HGG patients with EGFR alterations (Arm A) or EGFR fusions (Arm B) received 5 days of BDTX-1535 at 200 mg/daily (cohort 1) or 400 mg/every other day (cohort 2) prior to planned resection at 2-4 hours following the final dose. In the Phase 0 component of...
Black Diamond also presented two additional posters outlining the study design of the ongoing Phase 1 clinical trial of BDTX-1535 in NSCLC and preclinical data for BDTX-4933, a brain-penetrant MasterKey RAF inhibitor targeting KRAS, ...
The phase 2 trial began in August of 2023, and enrolled relapsed/refractory patients with non-classical EGFR mutations (NCMs) (Cohort 1) and those with C797S resistance mutations (Cohort 2). Safety assessment and dose selection were based upon the first 40 patients randomized to...
We have amivantamab-vmjw [Rybrevant], patritumab deruxtecan [HER3-DXd], and other drugs coming out, but for patients who develop these C797S mutations, that’s a huge area of unmet need and that’s what the real focus of this [trial] is going to be. In the area of atypical...
The safety, tolerability, pharmacokinetics, and preliminary antitumor activity of the EGFR inhibitor BDTX-1535 are currently under investigation in the phase 1 BDTX-1535-101 trial (NCT05256290) in patients with recurrent glioblastoma or locally advanced or metastatic NSCLC with or without central nervous...
图片来自:医药魔方TrialCube数据库 此次公布的初步结果仅限于队列1和队列2。企业提供的22名患者数据显示,19名患者存在PACC-NCM或C797S突变,3名患者存在其他NCM突变。 安全性数据方面,截止2024年6月15日,共有40名患者随机分配到100 mg(n=20)或200 mg组(n=20) (不论是在队列1还是队列2) 。
图片来自:医药魔方TrialCube数据库 此次公布的初步结果仅限于队列1和队列2。企业提供的22名患者数据显示,19名患者存在PACC-NCM或C797S突变,3名患者存在其他NCM突变。 安全性数据方面,截止2024年6月15日,共有40名患者随机分配到100 mg(n=20)或200 mg组(n=20) (不论是在队列1还是队列2) 。
2069#Background:This Phase 0/1 clinical trial evaluates the pharmacokinetic (PK), pharmacodynamic (PD), and clinical response of recurrent high-grade glioma (HGG) patients with EGFR alterations and/or fusions to the ATP-competitive, irreversible EGFR inhibitor, BDTX-1535.Methods:Recurrent HGG ...
Given the inability to reconfirm EGFR status at the time of treatment with BDTX-1535 in this Phase 1 trial, further exploration of BDTX-1535 in a "window of opportunity" study is ongoing (NCT06072586).Clinical trial information: NCT05256290.Patrick Y. Wen...